Trials / Recruiting
RecruitingNCT07234942
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7812653 | Participants will receive RO7812653 as per the schedule in the protocol |
| DRUG | Placebo | Participants will receive placebo as per the schedule in the protocol |
Timeline
- Start date
- 2026-01-27
- Primary completion
- 2028-04-19
- Completion
- 2030-03-05
- First posted
- 2025-11-19
- Last updated
- 2026-04-03
Locations
5 sites across 3 countries: Netherlands, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT07234942. Inclusion in this directory is not an endorsement.